Antiviral Activity of Double-Stranded Ribonucleic Acid and Interferon Alpha Composition in the Model of Experimental Influenza Infection of Mice-Reference-Cited by-同舟云学术

Antiviral Activity of Double-Stranded Ribonucleic Acid and Interferon Alpha Composition in the Model of Experimental Influenza Infection of Mice

Published:2023-12-25 Issue:7-8 Volume:68 Page:27-33
ISSN:0235-2990
Container-title:Antibiotics and Chemotherapy
language:
Short-container-title:A&Ch

Author:

Gamaley S. G.¹,Skarnovich М. O.¹,Makarevich E. V.¹,Mazurkov О. Yu.¹,Shishkina L. N.¹^ORCID,Ivanova О. S.¹^ORCID,Levagina G. M.¹^ORCID,Danilenko Е. D.¹^ORCID

Affiliation:

1. State Research Center of Virology and Biotechnology «Vector» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Abstract

High variability of influenza viruses requires the development of agents for nonspecific resistance stimulation, along with the development of new drugs for prevention and treatment. Among the antiviral drugs, interferons and their inducers are known to exhibit a universally wide spectrum of action. The Institute of Medical Biotechnology, a branch of SRC VB «Vector», Rospotrebnadzor, has developed the technology and obtained pharmaceutical compositions containing an interferon inducer — double stranded ribonucleic acid (dsRNA) from the killer strain of Saccharomyces cerevisiae yeast and recombinant human interferon-alpha-2b (IFN- alpha-2b). The specific antiviral activity of the preparations and synergistic effect of the components within the compositions were shown in L-68 and L-929 cell cultures. The aim of this work was to study antiviral activity of intranasal forms of the pharmaceutical compositions containing yeast dsRNA and recombinant human interferon-alpha-2b in a model of lethal influenza infection in mice. The outbred ICR/CD1 mice were intranasally infected with influenza A/Aichi/2/68 (H3N2) virus. The study compositions were intranasally administered 3 hours before infection with influenza virus, as well as 1 and 3 days post infection. The doses of active components in the administered compositions were as follows: for dsRNA — 2.5 mg/kg, for IFN-alpha-2b — 500 IU/kg, 2500 IU/kg, or 5000 IU/kg. The antiviral activity of the drugs was assessed based on the mortality rate and the average life expectancy of mice. It was shown that a three-time intranasal administration of the composition of dsRNA (2.5 mg/kg) and IFN-alpha-2b (2500 IU) into the infected mice according to therapeutic-prophylactic regimen led to an increase in the rates of survival and average life expectancy of animals, which were comparable to the effect of Tamiflu. The comparison preparations — dsRNA and IFN-alpha-2b — administered intranasally at the same doses and regimen exerted no antiviral effect in this mouse model of viral infection. The data obtained confirm the prospects for further development of new dosage forms of dsRNA and interferons for intranasal application as agents for prevention and treatment of influenza.

Publisher

Publishing House OKI

Subject

Infectious Diseases,Microbiology (medical),General Medicine,Microbiology

Reference12 articles.

1. Deryabin P.G., Galegov G.A., Botikov A.G., Burtseva V.I., Mishin D.V., Shchelkanov M.Yu. Effect of zanamivir substance on infection induced by highly pathogenic avian influenza A/H5N1 in cell cultures. Voprosy Virusologii. 2011; 56 (1): 21-24 (in Russian)

2. Burtseva Ye.I., Breslav N.V., Kirillova Ye.S., Kolobukhina L.V., Prilipov A.G., Malyshev N.A. et. al. Influenza virus neuraminidase inhibitors: efficacy during post-pandemics period. Effektivnaya Farmakoterapiya. 2017; (3): 28–32. https://nomides.ru/files/ingibitory-nejraminidazy-virusov-grippa.-jeffektivnost-v-postpandemicheskij-period.pdf (in Russian)

3. Ryazantsev S.V., Khmel'nitskaya N.M, Tyrnova Ye.V. Rol' slizistoy obolochki v zashchite LOR organov ot potentsial'no patogennykh dlya organizma antigennykh faktorov. Vestnik Otolaringologii. 2000; (3): 60–63. (in Russian)

4. Oslund K.L., Zhou X., Lee B., Zhu L., Duong T., Shih R. et al. Synergistic up-regulation of CXCL10 by virus and IFN-γ in human airway epithelial cells. PLoS One. 2014; 9 (7): e100978. doi: 10.1371/journal.pone.0100978.

5. Osidak L.V., Afanasyeva O.I., Golovacheva E.G., Gonchar V.V., Pisareva M.M., Dondurey E.A. et.al. Recombinant interferon α-2b (Grippferon) in the treatment and prevention of acute respiratory viral infections. Pharmateka; 27 (1): 80–91. doi: https://doi.org/10.18565/pharmateca.2020.1.80- 91. (in Russian)